nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
|
Sweeney, Christopher J. |
|
2009 |
66 |
2 |
p. 345-356 |
artikel |
2 |
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
|
Cohen, Steven J. |
|
2009 |
66 |
2 |
p. 287-294 |
artikel |
3 |
Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?
|
Ishii, Yukimoto |
|
2009 |
66 |
2 |
p. 333-343 |
artikel |
4 |
Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
|
Greene, Daniel P. |
|
2009 |
66 |
2 |
p. 265-267 |
artikel |
5 |
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
|
Choi, Yun Jung |
|
2009 |
66 |
2 |
p. 381-388 |
artikel |
6 |
Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo
|
Ye, Xiaolei |
|
2010 |
66 |
2 |
p. 277-285 |
artikel |
7 |
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
|
Helsby, N. A. |
|
2010 |
66 |
2 |
p. 405-407 |
artikel |
8 |
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
|
Thompson, Karol L. |
|
2009 |
66 |
2 |
p. 303-314 |
artikel |
9 |
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase
|
RĂ©ti, Andrea |
|
2009 |
66 |
2 |
p. 219-227 |
artikel |
10 |
Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
|
Todorova, Valentina K. |
|
2009 |
66 |
2 |
p. 315-323 |
artikel |
11 |
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
|
Caponigro, F. |
|
2009 |
66 |
2 |
p. 389-394 |
artikel |
12 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
|
Buch-Hansen, Trine Zeeberg |
|
2009 |
66 |
2 |
p. 295-301 |
artikel |
13 |
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer
|
Sym, Sun Jin |
|
2009 |
66 |
2 |
p. 373-380 |
artikel |
14 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents
|
Goteti, Kosalaram |
|
2009 |
66 |
2 |
p. 245-254 |
artikel |
15 |
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
|
Fujimoto-Ouchi, Kaori |
|
2009 |
66 |
2 |
p. 269-276 |
artikel |
16 |
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials
|
Nasti, G. |
|
2010 |
66 |
2 |
p. 209-218 |
artikel |
17 |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
|
Houk, Brett E. |
|
2009 |
66 |
2 |
p. 357-371 |
artikel |
18 |
Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines
|
Horio, Yoshitsugu |
|
2009 |
66 |
2 |
p. 237-243 |
artikel |
19 |
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
|
Mitry, Emmanuel |
|
2010 |
66 |
2 |
p. 395-403 |
artikel |
20 |
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy
|
Katta, Anilkumar |
|
2010 |
66 |
2 |
p. 409-412 |
artikel |
21 |
Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
|
Lee, Su Jin |
|
2009 |
66 |
2 |
p. 229-235 |
artikel |
22 |
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
|
Radujkovic, Aleksandar |
|
2009 |
66 |
2 |
p. 255-264 |
artikel |
23 |
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
|
Sookraj, Kelley A. |
|
2010 |
66 |
2 |
p. 325-331 |
artikel |